Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein
28 juin 2023 03h30 HE
|
Philogen
Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein Siena, Italy, 28th June 2023 – Philogen S.p.A (BIT: PHIL) today announced that it has...
Philogen Announces Clinical Trial Collaboration with MSD
01 juin 2023 02h30 HE
|
Philogen
The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and...
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
30 mai 2023 01h00 HE
|
Philogen
Mumbai, India and Siena, Italy, 30th May 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or...
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
25 mai 2023 02h00 HE
|
Philogen
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich L19TNF (also known as Fibromun) is an...
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries
07 nov. 2022 11h07 HE
|
Philogen
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries The study highlights the application of DNA-Encoded Chemical...
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma
25 juil. 2022 08h00 HE
|
Philogen
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma 214 patients recruited in the study, in line with...
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS
24 nov. 2021 03h00 HE
|
Philogen
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS Siena, Italy, November 24, 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody...
Philogen Provides Corporate Update
12 nov. 2021 02h00 HE
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun are on track with planned timelines in pivotal clinical trialsFibromun shows potent activity in last-line glioblastoma in combination with...
Philogen Provides Corporate Update
29 sept. 2021 04h58 HE
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
12 mai 2021 13h00 HE
|
Philogen
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress May 12, 2021 NidlegyTM on track for Phase III European trial in stage IIIB/C melanoma. Opening of additional...